The relationship between resting-state functional connectivity, antidepressant discontinuation and depression relapse.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
18 12 2020
Historique:
received: 19 06 2020
accepted: 26 11 2020
entrez: 19 12 2020
pubmed: 20 12 2020
medline: 29 4 2021
Statut: epublish

Résumé

The risk of relapsing into depression after stopping antidepressants is high, but no established predictors exist. Resting-state functional magnetic resonance imaging (rsfMRI) measures may help predict relapse and identify the mechanisms by which relapses occur. rsfMRI data were acquired from healthy controls and from patients with remitted major depressive disorder on antidepressants. Patients were assessed a second time either before or after discontinuation of the antidepressant, and followed up for six months to assess relapse. A seed-based functional connectivity analysis was conducted focusing on the left subgenual anterior cingulate cortex and left posterior cingulate cortex. Seeds in the amygdala and dorsolateral prefrontal cortex were explored. 44 healthy controls (age: 33.8 (10.5), 73% female) and 84 patients (age: 34.23 (10.8), 80% female) were included in the analysis. 29 patients went on to relapse and 38 remained well. The seed-based analysis showed that discontinuation resulted in an increased functional connectivity between the right dorsolateral prefrontal cortex and the parietal cortex in non-relapsers. In an exploratory analysis, this functional connectivity predicted relapse risk with a balanced accuracy of 0.86. Further seed-based analyses, however, failed to reveal differences in functional connectivity between patients and controls, between relapsers and non-relapsers before discontinuation and changes due to discontinuation independent of relapse. In conclusion, changes in the connectivity between the dorsolateral prefrontal cortex and the posterior default mode network were associated with and predictive of relapse after open-label antidepressant discontinuation. This finding requires replication in a larger dataset.

Identifiants

pubmed: 33339879
doi: 10.1038/s41598-020-79170-9
pii: 10.1038/s41598-020-79170-9
pmc: PMC7749105
doi:

Substances chimiques

Antidepressive Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

22346

Références

Psychiatry Res. 2015 Nov 30;234(2):164-71
pubmed: 26411798
J Psychiatr Res. 2015 Dec;71:103-11
pubmed: 26468907
Soc Neurosci. 2013;8(5):417-33
pubmed: 23826933
Neuroimage. 2017 Jul 1;154:128-149
pubmed: 27956209
Neuroreport. 2015 Aug 19;26(12):675-80
pubmed: 26164454
Mol Psychiatry. 2017 Mar;22(3):450-457
pubmed: 27090303
JAMA Psychiatry. 2015 Jun;72(6):603-11
pubmed: 25785575
Psychol Med. 2017 Feb;47(3):426-437
pubmed: 27786144
Transl Psychiatry. 2018 Mar 6;8(1):57
pubmed: 29507282
Neurosci Biobehav Rev. 2015 Sep;56:330-44
pubmed: 26234819
World Psychiatry. 2013 Feb;12(1):44-52
pubmed: 23471801
Neuroimage. 2012 Feb 1;59(3):2142-54
pubmed: 22019881
Psychol Med. 2017 Mar;47(4):597-607
pubmed: 27821193
JAMA Psychiatry. 2013 Apr;70(4):373-82
pubmed: 23389382
Behav Res Methods. 2009 Nov;41(4):1149-60
pubmed: 19897823
Hum Brain Mapp. 2015 Feb;36(2):768-78
pubmed: 25332057
Eur Arch Psychiatry Clin Neurosci. 2003 Oct;253(5):236-40
pubmed: 14504992
Sci Rep. 2017 Aug 31;7(1):10214
pubmed: 28860564
Neuroimage Clin. 2016 Mar 02;16:390-398
pubmed: 28861340
Proc Natl Acad Sci U S A. 2013 Nov 19;110(47):19119-24
pubmed: 24191026
Psychol Med. 1996 May;26(3):477-86
pubmed: 8733206
Clin Psychol Rev. 2010 Mar;30(2):217-37
pubmed: 20015584
Lancet. 2003 Feb 22;361(9358):653-61
pubmed: 12606176
J Child Adolesc Psychopharmacol. 2016 Oct;26(8):705-712
pubmed: 27159204
Cogn Affect Behav Neurosci. 2017 Dec;17(6):1242-1254
pubmed: 29110183
Biol Psychiatry. 2014 Oct 1;76(7):527-35
pubmed: 24462230
Neuropsychopharmacology. 2016 Jul;41(8):2082-90
pubmed: 26781519
Biol Psychiatry. 2013 Jul 1;74(1):48-54
pubmed: 23273724
Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):11020-5
pubmed: 20534464
Trends Cogn Sci. 2005 May;9(5):242-9
pubmed: 15866151
Neuroimage. 2018 Oct 15;180(Pt A):68-77
pubmed: 28655633
Neuropsychiatr Dis Treat. 2011;7(Suppl 1):3-7
pubmed: 21750622
N Engl J Med. 2006 Mar 23;354(12):1231-42
pubmed: 16554525
Psychiatry Res. 2013 Dec 30;214(3):313-21
pubmed: 24144505
Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9673-8
pubmed: 15976020
Psychol Med. 2016 Apr;46(5):1055-67
pubmed: 26784396
J Child Psychol Psychiatry. 2012 Sep;53(9):964-72
pubmed: 22519864
Nat Hum Behav. 2019 Aug;3(8):768-771
pubmed: 31253883
Biol Psychiatry. 2007 Sep 1;62(5):429-37
pubmed: 17210143
Proc Natl Acad Sci U S A. 2019 Apr 30;116(18):9078-9083
pubmed: 30979801
Brain Connect. 2012;2(3):125-41
pubmed: 22642651
Neuroimage Clin. 2018;20:1001-1009
pubmed: 30321791
Neuroreport. 1997 Mar 3;8(4):1057-61
pubmed: 9141092
Front Psychiatry. 2018 Jun 08;9:244
pubmed: 29937738
Neuropsychopharmacology. 2005 Jul;30(7):1334-44
pubmed: 15856081
Biol Psychiatry. 2016 Dec 1;80(11):849-858
pubmed: 26826874
Soc Cogn Affect Neurosci. 2015 Nov;10(11):1460-8
pubmed: 25836993
Dialogues Clin Neurosci. 2014 Dec;16(4):479-90
pubmed: 25733953
J Affect Disord. 2015 Feb 1;172:8-17
pubmed: 25451389
PLoS One. 2014 Aug 27;9(8):e104366
pubmed: 25162661
Front Neurol. 2019 Apr 24;10:420
pubmed: 31068901
Biol Psychiatry Cogn Neurosci Neuroimaging. 2016 Jan;1(1):68-76
pubmed: 26709390

Auteurs

Isabel M Berwian (IM)

Translational Neuromodeling Unit, University of Zurich and ETH Zurich, Zurich, Switzerland. iberwian@princeton.edu.
Hospital of Psychiatry, University of Zurich, Zurich, Switzerland. iberwian@princeton.edu.
Princeton Neurosciene Institute, Princeton University, Princeton, USA. iberwian@princeton.edu.

Julia G Wenzel (JG)

Charité Universitätsmedizin, Campus Charité Mitte, Berlin, Germany.

Leonie Kuehn (L)

Charité Universitätsmedizin, Campus Charité Mitte, Berlin, Germany.

Inga Schnuerer (I)

Translational Neuromodeling Unit, University of Zurich and ETH Zurich, Zurich, Switzerland.

Lars Kasper (L)

Translational Neuromodeling Unit, University of Zurich and ETH Zurich, Zurich, Switzerland.
Institute of Biomedical Engineering, ETH Zurich and University of Zurich, Zurich, Switzerland.

Ilya M Veer (IM)

Charité Universitätsmedizin, Campus Charité Mitte, Berlin, Germany.

Erich Seifritz (E)

Hospital of Psychiatry, University of Zurich, Zurich, Switzerland.

Klaas E Stephan (KE)

Translational Neuromodeling Unit, University of Zurich and ETH Zurich, Zurich, Switzerland.
Wellcome Trust Centre for Neuroimaging, University College London, London, UK.
Max Planck Institute for Metabolism Research, Cologne, Germany.

Henrik Walter (H)

Charité Universitätsmedizin, Campus Charité Mitte, Berlin, Germany.

Quentin J M Huys (QJM)

Translational Neuromodeling Unit, University of Zurich and ETH Zurich, Zurich, Switzerland.
Hospital of Psychiatry, University of Zurich, Zurich, Switzerland.
Division of Psychiatry and Max Planck Centre for Computational Psychiatry and Ageing Research, University College London, London, UK.
Camden and Islington NHS Foundation Trust, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH